Amir Abdollahi
YOU?
Author Swipe
View article: Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas Open
Drug Screening Data
View article: 3D RANGE MODULATORS FOR FLASH CARBON ION THERAPY: DESIGN, SIMULATION, AND VALIDATION
3D RANGE MODULATORS FOR FLASH CARBON ION THERAPY: DESIGN, SIMULATION, AND VALIDATION Open
View article: Supplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Table S5. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the validation cohort (DKTK-ROG)
View article: Supplementary Figures S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figures S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Figure 1. (Top) Venn Diagram showing the intersect between Hypoxia-M V2 significant DMPs (n=3397) and Hypoxia-M V1 significant DMPs (n=5129) 2551 (66%) of significant DMPs identified based on the 85th percentile of standard d…
View article: Supplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Table S4. Correlations with CIBERSORT immune signature expressions in the TCGA-HNSCC cohort
View article: Supplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p<0.002) (Bottom) Hypoxia-M V2 is an independent prognosticator of OS (HR=1.81, p<0.03) after adjusting for demographic and clinical f…
View article: Supplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Table S6. Contingency Table of Hypoxia-M and CD8-immunohistochemistry (IHC) staining for CD8-T cells
View article: RBE MODEL COMPARISON OF RECURRENT HIGH-GRADE GLIOMA PATIENTS AFTER CARBON ION RE-IRRADIATION USING DOSIOMICS
RBE MODEL COMPARISON OF RECURRENT HIGH-GRADE GLIOMA PATIENTS AFTER CARBON ION RE-IRRADIATION USING DOSIOMICS Open
View article: Supplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Methods, Results, Table of Contents
View article: Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Statistical Output
View article: Supplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS), local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) Af…
View article: Supplementary Table S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Table S2. Treatment Information for the validation cohort (n=88, DKTK-ROG)
View article: Supplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort. Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death (p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.02…
View article: Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas Open
Supplementary Figures
View article: Supplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy Open
Supplementary Table S1. Multivariate Analysis for the Hypoxia-M and Brooks signature.
View article: EXTH-146. The Pharmacological Atlas of Meningiomas
EXTH-146. The Pharmacological Atlas of Meningiomas Open
There are currently no systemic treatment options available for patients with recurrent or refractory meningiomas. This study aims to address this gap by developing a comprehensive pharmacological atlas of FDA-approved oncology drugs using…
View article: DDDR-21. Characterizing novel patient-derived breast cancer brain metastases models through high-throughput drug screening and integrative omics profiling
DDDR-21. Characterizing novel patient-derived breast cancer brain metastases models through high-throughput drug screening and integrative omics profiling Open
The development of breast cancer brain metastases (BCBM) is among the most critical predictive factors for patient survival. However, understanding the drug sensitivity of BCBM cells to various drugs, particularly in terms of how effective…
View article: Cardiac Troponin I Antibodies Induce Cardiomyocyte Damage and Alter Cell Morphology
Cardiac Troponin I Antibodies Induce Cardiomyocyte Damage and Alter Cell Morphology Open
Circulating heart-reactive autoantibodies (aAbs) detected in a variety of heart diseases (e.g., myocarditis, dilated cardiomyopathy, and myocardial infarction) have been associated with the progression of heart failure and a poor prognosis…
View article: P11.37.B NOVEL PATIENT-DERIVED BREAST CANCER BRAIN METASTASES MODELS CHARACTERIZED BY LARGE-SCALE DRUG SCREENING AND INTEGRATIVE MULTI-OMICS PROFILING
P11.37.B NOVEL PATIENT-DERIVED BREAST CANCER BRAIN METASTASES MODELS CHARACTERIZED BY LARGE-SCALE DRUG SCREENING AND INTEGRATIVE MULTI-OMICS PROFILING Open
BACKGROUND The development brain metastases is among the most critical predictive factors for breast cancer patient survival. At the same time, personalized selection of effective drugs against BCBM is particularly challenging due to vario…
View article: KS03.5.A DISSECTING THE CELLULAR ARCHITECTURE OF BREAST CANCER BRAIN METASTASES REVEALS PROGNOSTICALLY DISTINCT IMMUNE LANDSCAPES
KS03.5.A DISSECTING THE CELLULAR ARCHITECTURE OF BREAST CANCER BRAIN METASTASES REVEALS PROGNOSTICALLY DISTINCT IMMUNE LANDSCAPES Open
BACKGROUND Breast cancer brain metastases are associated with a poor prognosis, and there is a high demand for improved personalized treatment strategies. It is still poorly understood which breast cancer brain metastases patients benefit …
View article: Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after radiation
Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after radiation Open
Background Thoracic radiotherapy is still the treatment of choice for many oncological diseases. Despite state-of-the-art radiation techniques, patient-centred and personalized radiation of the tumours, patients who undergo thoracic radiot…
View article: First in vitro and in vivo experiments with ultra high-dose rate oxygen ion radiotherapy
First in vitro and in vivo experiments with ultra high-dose rate oxygen ion radiotherapy Open
View article: HyperSHArc: Single-Isocenter Stereotactic Radiosurgery of Multiple Brain Metastases Using Proton, Helium, and Carbon Ion Arc Therapy
HyperSHArc: Single-Isocenter Stereotactic Radiosurgery of Multiple Brain Metastases Using Proton, Helium, and Carbon Ion Arc Therapy Open
View article: Effect of Paxlovid on Skeletal System Morphogenesis in Animal Model Rat (Morphological Study)
Effect of Paxlovid on Skeletal System Morphogenesis in Animal Model Rat (Morphological Study) Open
The findings suggest that while there are observable effects on maternal weight and fetal growth parameters, the administration of Paxlovid did not result in skeletal system abnormalities in the embryos. This research indicates a minimal r…
View article: Real-time adaptive proton therapy: An AI-based spatio-temporal mono-energetic dose calculation model (CC-LSTM)
Real-time adaptive proton therapy: An AI-based spatio-temporal mono-energetic dose calculation model (CC-LSTM) Open
CC-LSTM can effectively learn the dose estimation task and generalize to unseen patient cases, achieving accuracies comparable to the gold-standard Monte Carlo simulations for highly heterogeneous cases, while maintaining runtimes suitable…
View article: Ultrahigh Dose Rate Helium Ion Beams: Minimizing Brain Tissue Damage while Preserving Tumor Control
Ultrahigh Dose Rate Helium Ion Beams: Minimizing Brain Tissue Damage while Preserving Tumor Control Open
Ultrahigh dose rate radiotherapy (RT) with electrons and protons has shown potential for cancer treatment by effectively targeting tumors while sparing healthy tissues (FLASH effect). This study aimed to investigate the potential FLASH spa…
View article: Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing
Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing Open
View article: Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat
Personalized Medicine for Meningiomas: Drug Screening on Tumor Organoids Exposes Therapeutic Vulnerabilities to HDAC1/2i Panobinostat Open
SUMMARY Managing aggressive meningiomas remains challenging due to limited treatment options besides surgical tumor removal and radiotherapy. To identify novel therapies for aggressive meningiomas, we established a multi-step drug screenin…
View article: Spatio-temporal transcriptomics of chromothriptic SHH-medulloblastoma identifies multiple genetic clones that resist treatment and drive relapse
Spatio-temporal transcriptomics of chromothriptic SHH-medulloblastoma identifies multiple genetic clones that resist treatment and drive relapse Open
View article: Oxygen consumption measurements at ultra‐high dose rate over a wide LET range
Oxygen consumption measurements at ultra‐high dose rate over a wide LET range Open
Background The role of radiolytic oxygen consumption for the in‐vitro “Ultra‐High Dose Rate” (UHDR) sparing and in‐vivo FLASH effect is subject to active debate, but data on key dependencies such as the radiation quality are lacking. Purpo…